Adolfo Aleman

9PUBLICATIONS
69CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 08, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

|Nov 05, 2025
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman

|Aug 13, 2025
Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar

|May 13, 2025
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells.

Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar

|Nov 03, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.

Oliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine

|Aug 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.

Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff

Pageof 2

Frequent Collaborators

6 joint publications

Hearn Jay Cho

5 joint publications

Sundar Jagannath

5 joint publications

Joshua Richter

4 joint publications

Santiago Thibaud